Cargando…

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

Detalles Bibliográficos
Autores principales:	Del Re, M., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., Piacentini, F., Fogli, S., De Giorgi, U., Danesi, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897157/ https://www.ncbi.nlm.nih.gov/pubmed/35131649 http://dx.doi.org/10.1016/j.esmoop.2022.100381

Ejemplares similares

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Beechinor, R., et al.
Publicado: (2022)

Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer
por: Altundag, Kadri
Publicado: (2022)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020)

Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’: [ESMO Open Volume 7, Issue 1, February 2022, 100393]
por: Beechinor, R., et al.
Publicado: (2022)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Authors' Reply to “Translating palbociclib to the clinic for DIPG - What is truly achievable?”
por: Sun, Yu, et al.
Publicado: (2019)

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
por: Lee, Ju-Eun, et al.
Publicado: (2023)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

Author reply: comment on the drug utilization pattern in chronic obstructive pulmonary disease
por: Veettil, Sajesh Kalkandi, et al.
Publicado: (2015)

Reply to the comment
por: Okada, Yohei, et al.
Publicado: (2020)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE
por: Dismuke, Taylor, et al.
Publicado: (2020)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Author reply to comments
por: Bhalla, Ashu Seith, et al.
Publicado: (2015)

Author’s Reply: Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”
por: Liu, Mou-Ze, et al.
Publicado: (2017)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Reply to the Comment of G. Feulner
por: Weber, Werner
Publicado: (2011)

Reply to the Comments from Readers
por: Wang, Min, et al.
Publicado: (2018)

Reply to the Comment by Littlechild and Isupov
por: Willetts, Andrew, et al.
Publicado: (2017)

Reply to comment on: The Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2021)

AUTHOR REPLY TO EDITORIAL COMMENT
por: Shiff, Benjamin, et al.
Publicado: (2021)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
por: Eser, Kadir, et al.
Publicado: (2022)

Eﬄux pump-mediated drug resistance in Burkholderia
por: Podnecky, Nicole L., et al.
Publicado: (2015)

De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial
por: Banini, Marco, et al.
Publicado: (2023)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dk842jfnhg4m2ks9hf1sq74uck